Company Description
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis.
It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza.
The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006.
AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Jan 26, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Daniel Faga |
Contact Details
Address: 10770 Wateridge Circle, Suite 210 San Diego, California 92121 United States | |
| Phone | 858 362 6295 |
| Website | anaptysbio.com |
Stock Details
| Ticker Symbol | ANAB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001370053 |
| CUSIP Number | 032724106 |
| ISIN Number | US0327241065 |
| Employer ID | 20-3828755 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel R. Faga | President, Chief Executive Officer and Director |
| Christopher M. Murphy | Chief Financial Officer |
| Beth Mueller | Senior Vice President of Human Resources |
| Benjamin Stone | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 1, 2026 | 144 | Filing |
| Sep 21, 2026 | 10-KT | Filing |
| Sep 21, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 13, 2026 | 144 | Filing |
| Jun 30, 2026 | 144 | Filing |
| Jun 29, 2026 | 144 | Filing |
| Jun 29, 2026 | ARS | Filing |